Document is current
Any future updates will be listed below
-
Authors
Bermack, Casey
Singh, Shailbala https://orcid.org/0000-0002-0681-3948
Pei, Guangsheng
Patel, Sapna P
Wang, Linghua
Yee, Cassian
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03068624 at ClinicalTrials.govDocuments that mention this clinical trial
First-in-human use of recombinant IL-7 to potentiate antigen-specific T cell therapy: a single patient case study
https://doi.org/10.1136/jitc-2026-014822
A phase Ib study of endogenous T cell therapy using SLC45A2-specific CD8 T cells for patients with metastatic uveal melanoma.
https://doi.org/10.1200/jco.2023.41.16_suppl.9588
-
Funding
Funding for this research was provided by:
Cancer Prevention and Research Institute of Texas (RP190360)
STrategic Research Initiative DEvelopment (STRIDE) program at The University of Texas MD Anderson Cancer Center (Program for TCR-based Therapeutics (ProTCT))
- License Information
